ImmunoMet 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lixumistat (IM156) / ImmunoMet
NCT05497778: A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Recruiting
1
25
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab paclitaxel, Paclitaxel (protein-bound), Abraxane, ABI-007, IM156
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pancreas Cancer
02/27
02/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lixumistat (IM156) / ImmunoMet
NCT05497778: A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Recruiting
1
25
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab paclitaxel, Paclitaxel (protein-bound), Abraxane, ABI-007, IM156
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pancreas Cancer
02/27
02/27

Download Options